Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (101 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 59 | 0.73 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7672
Sealed predictions
- NPTXR in dopamine neurons, braak-0.23 (p 0.549) → +0.02 (p 0.964)receipt 7680
Swarm cases
receipt 7680: NPTXR in dopamine neurons, braak
- power
- full sample -0.06 (p 0.814, n 18), 95% CI -0.51 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.761, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.258, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.06, sign flips 4; without severely affected donors -0.06 (p 0.814, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0055, n 18) vs -0.06 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NPTXR in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NPTXR · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.52 p 0.062 (needs p < 2.7e-4)
Receipts
loading the receipts